Genfit Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Genfit ha aumentado sus beneficios a una tasa media anual de 38.1%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 7.7% anual. Los ingresos han ido creciendo a una tasa media de 17.2% al año. La rentabilidad financiera de Genfit es de 22.9%, y sus márgenes netos son de 27.7%.

Información clave

38.1%

Tasa de crecimiento de los beneficios

44.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	30.8%
Tasa de crecimiento de los ingresos	17.2%
Rentabilidad financiera	22.9%
Margen neto	27.7%
Última actualización de beneficios	30 Jun 2024

Actualizaciones de resultados anteriores recientes

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Sep 27

Recent updates

Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

Nov 16

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Sep 27

Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

Sep 26

Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%

Sep 24

Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Sep 22

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

May 23

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Sep 30

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Jun 29

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Mar 14

Is Genfit (EPA:GNFT) A Risky Investment?

Nov 28

Desglose de ingresos y gastos

Cómo gana y gasta dinero Genfit. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

ENXTPA:GNFT Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Jun 24	80	22	20	40
31 Mar 24	57	-3	19	43
31 Dec 23	34	-29	19	47
30 Sep 23	32	-32	18	45
30 Jun 23	29	-34	18	44
31 Mar 23	28	-29	18	40
31 Dec 22	26	-24	17	36
30 Sep 22	60	12	18	33
30 Jun 22	94	48	18	30
31 Mar 22	90	58	18	32
31 Dec 21	85	67	18	35
30 Sep 21	46	14	17	40
30 Jun 21	6	-39	16	45
31 Mar 21	7	-70	21	52
31 Dec 20	9	-101	25	59
30 Sep 20	24	-84	31	62
30 Jun 20	39	-67	36	64
31 Mar 20	39	-66	34	65
31 Dec 19	39	-65	31	66
30 Sep 19	23	-80	24	70
30 Jun 19	8	-94	18	74
31 Mar 19	8	-87	14	70
31 Dec 18	7	-80	10	67
30 Sep 18	7	-75	10	65
30 Jun 18	7	-70	11	63
31 Mar 18	7	-63	10	58
31 Dec 17	7	-56	9	54
30 Sep 17	7	-50	8	49
30 Jun 17	8	-44	7	44
31 Mar 17	7	-39	8	39
31 Dec 16	7	-34	8	33
30 Sep 16	6	-27	8	26
30 Jun 16	5	-21	7	20
31 Mar 16	5	-19	6	18
31 Dec 15	4	-17	6	16
30 Sep 15	5	-17	4	19
30 Jun 15	5	-17	3	23
31 Mar 15	6	-17	5	20
31 Dec 14	7	-17	6	18
30 Sep 14	7	-15	7	11
30 Jun 14	7	-14	8	5
31 Mar 14	6	-13	8	2
31 Dec 13	6	-13	7	0

Ingresos de calidad: GNFT tiene un alto nivel de ganancias no monetarias.

Margen de beneficios creciente: GNFT pasó a ser rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: GNFT ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 38.1% al año.

Acelerando crecimiento: GNFT ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su promedio de 5 años.

Beneficios vs. Industria: GNFT ha pasado a ser rentable en el último año, lo que es difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-20.8%).

Genfit Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

First half 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

Recent updates

Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

Investor sentiment deteriorates as stock falls 20%

Consensus EPS estimates increase by 21%, revenue downgraded

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Investor sentiment improves as stock rises 26%

Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

First half 2024 earnings: EPS and revenues exceed analyst expectations

Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%

Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

New minor risk - Share price stability

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

New minor risk - Share price stability

Genfit S.A., Annual General Meeting, May 22, 2024

Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 38%, EPS downgraded

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

New minor risk - Profitability

Consensus EPS estimates increase by 291%

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

Price target increased by 9.4% to €9.72

Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Consensus revenue estimates decrease by 21%

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Price target increased by 9.4% to €9.70

New minor risk - Share price stability

Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

Price target decreased by 11% to €8.84

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.1% to €9.20

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Consensus forecasts updated

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Genfit S.A. (ENXTPA:GNFT) acquired Versantis AG for approximately CHF 110 million.

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million.

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG from a group of investors for approximately CHF 110 million.

Consensus forecasts updated

Investor sentiment improved over the past week

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Consensus revenue estimates fall by 49%

Price target increased to €10.48

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 1,016%

Forecast to breakeven in 2022

Consensus forecasts updated

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

GENFIT Presents New NIS4® Data in NASH at the International Liver Congress™ and the 81St Scientific Sessions of the American Diabetes Association

GENFIT Announces the Launch of NASHnext®, a Novel, Noninvasive Diagnostic Test for Nonalcoholic Steatohepatitis

Full year 2020 earnings released: €2.61 loss per share (vs €1.76 loss in FY 2019)

Price target increased to €8.30

Full year 2020 earnings released

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

GENFIT Announces Board Changes

Genfit SA to Report Fiscal Year 2020 Results on Apr 01, 2021

Price target raised to €8.20

Genfit SA, Annual General Meeting, May 28, 2021

New 90-day high: €5.20

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology